Healthcare Sales & Marketing Network News: pruritus

Searching News Database: pruritus

HSMN NewsFeed - 12 Dec 2025
Alphyn Closes $25M Oversubscribed Series B Financing Round to Advance Dermatology Pipeline
Biopharmaceuticals Dermatology Venture Capital

HSMN NewsFeed - 25 Aug 2025
Akeso Reports Phase 3 Trials Show Positive Results: Gumokimab (IL-17) for Ankylosing Spondylitis and Manfidokimab (IL-4R?) for Atopic Dermatitis Achieve Primary Endpoints
Biopharmaceuticals

HSMN NewsFeed - 7 Feb 2025
Most Patients on Lilly's Omvoh(R) (mirikizumab-mrkz) for Crohn's Disease Achieved Sustained Clinical Remission and Endoscopic Response at Two Years
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 17 Jan 2025
FDA Approves LUMAKRAS(R) (Sotorasib) in Combination with Vectibix(R) (Panitumumab) for Chemorefractory KRAS G12C-Mutated Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 30 Dec 2024
Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig(TM) with ENHANZE(R) for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo(R) (nivolumab) Indications
Biopharmaceuticals Drug Delivery Oncology FDA

HSMN NewsFeed - 29 Oct 2024
Protega Pharmaceuticals Receives FDA Approval for ROXYBOND(TM) (oxycodone hydrochloride) Immediate-Release 10 mg Tablet with Abuse-Deterrent Technology for Management of Pain
Biopharmaceuticals FDA

HSMN NewsFeed - 25 Oct 2024
Lilly's EBGLYSS(TM) (lebrikizumab-lbkz) Demonstrated Meaningful Improvement in Skin Clearance and Itch Relief in the Majority of Patients with Moderate-To-Severe Atopic Dermatitis Who Discontinued Dupilumab
Biopharmaceuticals Dermatology

HSMN NewsFeed - 20 Aug 2024
RYBREVANT(R) (amivantamab-vmjw) Plus LAZCLUZE(TM) (lazertinib) Approved in the U.S. as a First-line Chemotherapy-free Treatment for Patients with EGFR-mutated Advanced Lung Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 16 Aug 2024
Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 9 Aug 2024
FDA Approves First Nasal Spray for Treatment of Anaphylaxis
Biopharmaceuticals Drug Delivery FDA

HSMN NewsFeed - 26 Mar 2024
Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS(R)
Biopharmaceuticals Generics Product Launch

HSMN NewsFeed - 11 Mar 2024
FDA Grants Orphan Drug and Pediatric Exclusivities for CRESEMBA(R) (isavuconazonium sulfate) for Invasive Aspergillosis and Invasive Mucormycosis in Children
Biopharmaceuticals FDA

HSMN NewsFeed - 15 Dec 2023
CymaBay Submits New Drug Application to FDA for Seladelpar for the Treatment of Primary Biliary Cholangitis
Biopharmaceuticals FDA

HSMN NewsFeed - 8 Sep 2023
Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration (FDA) regarding the Planned Resubmission of the BLA for LYMPHIR(TM)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 20 Jul 2023
Boehringer Ingelheim Receives FDA Approval for NexGard(R) PLUS (afoxolaner, moxidectin and pyrantel chewable tablets): A Beef-Flavored Soft Chew That Protects Dogs from Internal and External Parasites
Biopharmaceuticals Veterinary FDA

HSMN NewsFeed - 26 Sep 2022
Innocoll and DURECT Announce U.S. launch of POSIMIR(R)
Biopharmaceuticals Drug Delivery Product Launch

HSMN NewsFeed - 19 Sep 2022
AbbVie Secures Positive CHMP Opinion for Risankizumab (SKYRIZI(R)) for the Treatment of Adults with Moderate to Severe Crohn's Disease
Biopharmaceuticals Gastroenterology Regulatory

HSMN NewsFeed - 7 Jun 2022
Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly's Lebrikizumab Atopic Dermatitis Monotherapy Trials
Biopharmaceuticals Dermatology

HSMN NewsFeed - 13 May 2022
Medtronic completes acquisition of Intersect ENT
Devices Mergers & Acquisitions

HSMN NewsFeed - 4 Apr 2022
FDA approves Nobelpharma's HYFTOR(TM) (sirolimus topical gel) 0.2%
Biopharmaceuticals FDA

HSMN NewsFeed - 21 Dec 2021
Lilly's lebrikizumab demonstrated significant skin improvement and itch relief when combined with topical corticosteroids in people with atopic dermatitis in third Phase 3 study
Biopharmaceuticals Dermatology

HSMN NewsFeed - 13 Oct 2021
FDA Approves Verzenio(R) (abemaciclib) as the First and Only CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 27 Sep 2021
Japan's MHLW Approves PADCEV(R) (enfortumab vedotin) for Advanced Urothelial Cancer
Biopharmaceuticals Urology Oncology Regulatory

HSMN NewsFeed - 16 Sep 2021
LUMAKRAS(TM) (Sotorasib) Combined With Vectibix(R) (Panitumumab) Showed Encouraging Efficacy And Safety In Patients With KRAS G12C-Mutated Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 24 Aug 2021
European Commission Approves RINVOQ(R) (upadacitinib) as First JAK Inhibitor in the European Union for the Treatment of Both Adults and Adolescents with Moderate to Severe Atopic Dermatitis
Biopharmaceuticals Dermatology Regulatory

HSMN NewsFeed - 16 Aug 2021
Lilly's lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials
Biopharmaceuticals Dermatology

HSMN NewsFeed - 6 Aug 2021
FDA Approves New Treatment for Pompe Disease
Biopharmaceuticals FDA

HSMN NewsFeed - 16 Apr 2021
Lilly requests revocation of emergency use authorization for bamlanivimab alone to complete transition to bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S.
Biopharmaceuticals FDA

HSMN NewsFeed - 26 Mar 2021
European Medicines Agency Accepts Marketing Authorization Application for Enfortumab Vedotin
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 26 Feb 2021
Lilly announces additional doses of neutralizing antibody therapy purchased by U.S. government to treat COVID-19
Biopharmaceuticals

HSMN NewsFeed - 2 Feb 2021
DURECT Corporation Announces U.S. FDA Approval of POSIMIR(R) For Post-Surgical Pain Reduction for up to 72 Hours Following Arthroscopic Subacromial Decompression
Biopharmaceuticals Drug Delivery FDA

HSMN NewsFeed - 17 Dec 2020
FDA Approves GSK's BENLYSTA as the First Medicine for Adult Patients with Active Lupus Nephritis in the US
Biopharmaceuticals FDA

HSMN NewsFeed - 15 Dec 2020
Almirall announces FDA approval of Klisyri(R) (tirbanibulin), a new innovative topical treatment for actinic keratosis
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 15 Oct 2020
Titan Pharmaceuticals Provides a Strategic & Corporate Update
Biopharmaceuticals Personnel

HSMN NewsFeed - 24 Aug 2020
Connect Biopharma Completes $115 Million Series C Financing to Advance Ongoing Clinical Trials in Atopic Dermatitis and Ulcerative Colitis and Initiate Additional Clinical Programs
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 14 Aug 2020
Lupin Presents Phase 3 Data for Solosec(R) (secnidazole) Demonstrating Significant Response Rate in Female Patients with Trichomoniasis
Biopharmaceuticals

HSMN NewsFeed - 9 Mar 2020
Menlo Therapeutics and Foamix Pharmaceuticals Complete Merger, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications
Biopharmaceuticals Dermatology Mergers & Acquisitions

HSMN NewsFeed - 19 Feb 2020
Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for PADCEV(TM) (enfortumab vedotin-ejfv) in Combination with Pembrolizumab in First-Line Advanced Bladder Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 31 Jan 2020
AbbVie Receives Positive CHMP Opinion for MAVIRET(R) (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks in Genotype 3, Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 28 Jan 2020
Lilly plans donation of 200,000 insulin KwikPens over next three years to support lower-income communities
Biopharmaceuticals Drug Delivery Endocrinology

HSMN NewsFeed - 9 Dec 2019
HIZENTRA(R) (Immune Globulin Subcutaneous [Human] 20% Liquid) Receives Orphan-Drug Exclusivity for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 22 Oct 2019
Heron Announces FDA Approval of Supplemental New Drug Application to Expand CINVANTI(R) Label for Single-Dose Regimen for Patients Receiving Moderately Emetogenic Chemotherapy (MEC)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 23 Sep 2019
Mallinckrodt Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of StrataGraft(R) Regenerative Tissue in Patients with Deep Partial-thickness Thermal Burns
Regenerative Medicine

HSMN NewsFeed - 6 Aug 2019
Dupixent(R) (dupilumab) Approved by European Commission for Adolescents with Moderate-to-Severe Atopic Dermatitis
Biopharmaceuticals Dermatology Regulatory

HSMN NewsFeed - 1 Aug 2019
Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo(R) (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 30 Jul 2019
Lilly's Verzenio(R) (abemaciclib) Significantly Extended Life in Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Apr 2019
Alkermes Announces Positive Topline Results From Innovative Study of ARISTADA(R) and INVEGA SUSTENNA(R) for the Treatment of Schizophrenia
Biopharmaceuticals

HSMN NewsFeed - 18 Mar 2019
RDD Pharma Appoints John Temperato as Chief Executive Officer
Biopharmaceuticals Gastroenterology Personnel

HSMN NewsFeed - 12 Feb 2019
U.S. FDA Approves DARZALEX(R) (daratumumab) Split-Dosing Regimen
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 18 Dec 2018
Lilly Announces Publication of Analyses Showing Benefit of the Addition of Verzenio(R) (Abemaciclib) in Multiple Subgroups of Patients with Advanced Breast Cancer Identified as Having a More Concerning Prognosis
Biopharmaceuticals Oncology

HSMN NewsFeed - 23 Nov 2018
Indivior Announces Health Canada Approval of SUBLOCADE(TM) (Buprenorphine Extended-Release) Injection for Patients with Moderate to Severe Opioid Use Disorder
Biopharmaceuticals Regulatory

HSMN NewsFeed - 23 Oct 2018
Duchesnay Inc. Announces Submission of Supplemental New Drug Application (sNDA) for Osphena(R) (ospemifene) to U.S. FDA Seeking Approval for the Treatment of Vaginal Dryness, a Symptom of Vulvar and Vaginal Atrophy (VVA) Due to Menopause
Biopharmaceuticals FDA

HSMN NewsFeed - 13 Sep 2018
FDA Approves CroFab(R) Product Improvements
Biopharmaceuticals FDA

HSMN NewsFeed - 8 Aug 2018
Janssen Submits U.S. & EU Regulatory Applications Seeking Approval of DARZALEX(R) (daratumumab) Split Dosing Regimen
Biopharmaceuticals Oncology FDA Regulatory

HSMN NewsFeed - 27 Jun 2018
ANI Pharmaceuticals Announces Launch of Cholestyramine for Oral Suspension USP
Biopharmaceuticals Product Launch

HSMN NewsFeed - 8 Jun 2018
European Commission Approves Prolia(R) (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 6 Jun 2018
Partner Therapeutics (PTx) Announces US FDA Approval of Leukine(R) (sargramostim) for the Treatment of Acute Radiation Syndrome
Biopharmaceuticals FDA

HSMN NewsFeed - 5 Jun 2018
FDA Expands Lilly's ALIMTA(R) (pemetrexed) Label to Include Combination with KEYTRUDA(R) (pembrolizumab) and Carboplatin as First-Line Treatment for Metastatic Nonsquamous Non-Small Cell Lung Cancer, Irrespective of PD-L1 Expression
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 4 Jun 2018
RDD Pharma Appoints Dr. Mark Sirgo as Board Chairman
Biopharmaceuticals Gatroenterology Personnel

HSMN NewsFeed - 16 May 2018
Positive Phase 3 Trial of DUPIXENT(R) (dupilumab) in Adolescents with Inadequately Controlled Moderate-to-severe Atopic Dermatitis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 1 May 2018
SCYNEXIS's Oral SCY-078 Receives FDA QIDP and Fast Track Designations for the Treatment of VVC and Prevention of Recurrent VVC
Biopharmaceuticals FDA

HSMN NewsFeed - 27 Apr 2018
Amgen Receives Positive CHMP Opinion To Expand Use Of Prolia(R) (denosumab) To Patients With Glucocorticoid-Induced Osteoporosis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 23 Apr 2018
Theravance Biopharma Reports Positive New Data from Multiple Studies of VIBATIV(R) (telavancin) at 2018 ECCMID(TM) Conference
Biopharmaceuticals

HSMN NewsFeed - 16 Mar 2018
FDA Approves Hizentra(R) (Immune Globulin Subcutaneous [Human] 20% Liquid) for the Treatment of Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Biopharmaceuticals FDA

HSMN NewsFeed - 1 Mar 2018
SUBLOCADE(TM) (Buprenorphine Extended-Release) is Now Available as First and Only Monthly Injectable Buprenorphine in the U.S. to Treat Patients with Moderate to Severe Opioid Use Disorder
Biopharmaceuticals FDA Product Launch

HSMN NewsFeed - 23 Feb 2018
Amgen Receives Positive Opinion Expanding Use Of XGEVA(R) (denosumab) To Cover Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma In Europe
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 19 Feb 2018
AAD 2018: Treatment with Lilly's Taltz(R) (ixekizumab) Resulted in Improvement in Impact of Genital Psoriasis on Sexual Activity
Biopharmaceuticals Dermatology

HSMN NewsFeed - 13 Feb 2018
Sandoz announces US FDA approval and launch of Glatopa(R) 40 mg/mL three times-a-week generic option for relapsing forms of multiple sclerosis
Biopharmaceuticals Generics FDA Product Launch

HSMN NewsFeed - 1 Feb 2018
Partner Therapeutics (PTx) Acquires Leukine(R) from Sanofi
Biopharmaceuticals Oncology Acquisitions

HSMN NewsFeed - 10 Jan 2018
BYDUREON(R) BCise(TM) Injectable Medicine Now Available In The US For Patients With Type-2 Diabetes
Biopharmaceuticals Endocrinology Product Launch

HSMN NewsFeed - 5 Jan 2018
FDA Approves XGEVA(R) (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 12 Dec 2017
DARZALEX(R) (daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 Nov 2017
RDD Pharma Raises $9.5M in Series B Funding to Fuel Global Development
Biopharmaceuticals Gastroenterology Venture Capital

HSMN NewsFeed - 13 Nov 2017
Allergan Receives FDA Approval For Use of VRAYLAR(TM) (cariprazine) in the Maintenance Treatment of Schizophrenia
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 17 Oct 2017
Menlo Therapeutics Expands its Management Team
Biopharmaceuticals Dermatology Personnel

HSMN NewsFeed - 12 Oct 2017
FDA Grants Priority Review for Potential New Indication for Lilly's Verzenio(TM) (abemaciclib) as Initial Treatment of Advanced Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 7 Aug 2017
Impax Announces Settlement of Contract Litigation on Opana(R) ER (Oxymorphone Hydrochloride) CII Extended-Release Tablets
Biopharmaceuticals Litigation

HSMN NewsFeed - 18 Jul 2017
Menlo Therapeutics Raises $50M
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 19 Jun 2017
FDA Accepts Amgen's Supplemental Biologics License Application To Expand Indication For XGEVA(R) (denosumab) To Include Multiple Myeloma Patients
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 30 May 2017
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 Apr 2017
Novartis Receives FDA Approval for Rydapt(R) in Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML) and Three Types of Systemic Mastocytosis (SM)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 28 Mar 2017
Sanofi and Regeneron Announce FDA Approval of Dupixent(R) (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 24 Mar 2017
Richard Peterson Joins Sienna Biopharmaceuticals As Chief Financial Officer
Biopharmaceuticals Dermatology Personnel

HSMN NewsFeed - 22 Mar 2017
Allergan Announces Availability of RESTASIS MULTIDOSE(TM) (Cyclosporine Ophthalmic Emulsion) 0.05% -- the First FDA-Approved Preservative Free Prescription Eye Drop Available in a Multidose Bottle
Biopharmaceuticals Ophthalmology Product Launch

HSMN NewsFeed - 15 Mar 2017
FDA Approves Merck’s KEYTRUDA(R) (pembrolizumab) for Adult and Pediatric Patients with Classical Hodgkin Lymphoma (cHL) Refractory to Treatment, or Who Have Relapsed After Three or More Prior Lines of Therapy
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 20 Jan 2017
Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 27 Dec 2016
Shire Announces FDA Approval of Adynovate(R) for use in Children and Surgical Settings
Biopharmaceuticals FDA

HSMN NewsFeed - 19 Dec 2016
AbbVie Submits New Drug Application to U.S. FDA for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes of Chronic Hepatitis C
Biopharmaceuticals FDA

HSMN NewsFeed - 22 Nov 2016
DARZALEX(R) (daratumumab) Approved by U.S. FDA in Combination with Two Standard of Care Regimens for the Treatment of Patients with Multiple Myeloma Who Have Received At Least One Prior Therapy
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 11 Nov 2016
Bristol-Myers Squibb’s Opdivo(R) (nivolumab) is the First Immuno-Oncology Treatment to Receive FDA Approval Based on Overall Survival in Head and Neck Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 8 Nov 2016
Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Valeant for Contrave(R) (naltrexone HCl / bupropion HCl extended release) in Australia and New Zealand
Biopharmaceuticals Distribution

HSMN NewsFeed - 14 Oct 2016
Intercept Pharmaceuticals Receives Positive CHMP Opinion for Ocaliva(R) (Obeticholic Acid) for the Treatment of Primary Biliary Cholangitis in the European Union
Biopharmaceuticals Regulatory

HSMN NewsFeed - 14 Oct 2016
Bristol-Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) for the Treatment of Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant and Treatment With Brentuximab Vedotin
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 23 Sep 2016
AbbVie Presents Data on Eight-Week Treatment of VIEKIRAX(R) (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA(R) (dasabuvir tablets) in Patients with Genotype 1b Chronic Hepatitis C
Biopharmaceuticals

HSMN NewsFeed - 1 Aug 2016
Shire Announces FDA Approval of adynovate with BAXJECT III Reconstitution System
Biopharmaceuticals FDA

HSMN NewsFeed - 25 Jul 2016
CHMP Grants Positive Opinion for Shorter Treatment Duration with AbbVie's VIEKIRAX(R) (ombitasvir/paritaprevir/ritonavir tablets) for Patients with Genotype 4 Chronic Hepatitis C with Compensated Cirrhosis (Child-Pugh A)
Biopharmaceuticals Regulatory

HSMN NewsFeed - 27 Jun 2016
Merck Receives CHMP Positive Opinion for KEYTRUDA(R) (pembrolizumab) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 16 Jun 2016
Merck’s KEYTRUDA(R) (pembrolizumab) Demonstrates Superior Progression-Free and Overall Survival Compared to Chemotherapy as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Jun 2016
Orexigen Therapeutics Reports Favorable Markman Ruling in Contrave(R) Patent Litigation
Biopharmaceuticals Generics Litigation

HSMN NewsFeed - 23 May 2016
Egalet Settles Patent Litigations with Purdue Pharma
Biopharmaceuticals Litigation

HSMN NewsFeed - 9 May 2016
Theravance Biopharma Announces FDA Approval of Expanded Label for VIBATIV(R) (telavancin)
Biopharmaceuticals FDA

HSMN NewsFeed - 15 Apr 2016
AbbVie Announces Real-World Data with VIEKIRAX(R) (ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA(R) (dasabuvir tablets) from Large German Hepatitis C-Registry
Biopharmaceuticals

HSMN NewsFeed - 14 Apr 2016
New Analyses of the Phase 3 POISE Trial of Ocaliva(TM) (Obeticholic Acid) for the Treatment of PBC Presented at EASL
Biopharmaceuticals

HSMN NewsFeed - 16 Mar 2016
Allergan Announces U.S. Availability of VRAYLAR(TM) (cariprazine) for Treatment of Bipolar Mania and Schizophrenia in Adults
Biopharmaceuticals Product Launch

HSMN NewsFeed - 22 Feb 2016
Cipher Pharmaceuticals Inc. announces Canadian launch of Actikerall(TM)
Biopharmaceuticals Dermatology Product Launch

HSMN NewsFeed - 22 Feb 2016
Amgen And UCB Announce Positive Top-Line Results From The Phase 3 Study Of Romosozumab In Postmenopausal Women With Osteoporosis
Biopharmaceuticals

HSMN NewsFeed - 1 Feb 2016
Mallinckrodt Completes Acquisition Of Three Commercial-Stage, Global Specialty Hemostasis Brands From The Medicines Company
Devices Surgery Acquisitions

HSMN NewsFeed - 27 Jan 2016
Boehringer Ingelheim's Gilotrif(R) Demonstrated Superiority to Iressa(R) (Gefitinib) in Reducing the Risk of Disease Progression and Treatment Failure in First-Line Treatment of Patients with EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 21 Jan 2016
Allergan Announces FDA Approval of Updated Label for New Dosing Regimen for DALVANCE(R) (dalbavancin)
Biopharmaceuticals FDA

HSMN NewsFeed - 21 Dec 2015
Oral REVLIMID(R) Plus Dexamethasone Granted Approval for Treatment of Patients with Newly Diagnosed Multiple Myeloma in Japan
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 10 Dec 2015
Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA(R) Combination Trial
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Dec 2015
Teva Pharmaceuticals and Eagle Pharmaceuticals Announce FDA Approval of BENDEKA(TM) (bendamustine hydrochloride) Injection
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 24 Nov 2015
European Commission Approves Reconciliation of Indications for nivolumab Under the Opdivo(R) European Marketing Authorization Application
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 24 Nov 2015
Bristol-Myers Squibb Announces U.S. Food and Drug Administration Approval for Opdivo (nivolumab) as a Single Agent for the Treatment of Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 22 Oct 2015
Merrimack Announces U.S. FDA Approval of ONIVYDE(TM) (irinotecan liposome injection) for the Treatment of Patients with Metastatic Pancreatic Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 1 Oct 2015
Bristol-Myers Squibb Receives Approval from the U.S. Food and Drug Administration for the Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen in BRAF V600 Wild-Type Unresectable or Metastatic Melanoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 28 Sep 2015
Regeneron and Sanofi Announce Approval of Praluent(R) (alirocumab) for the Treatment of Hypercholesterolemia in the European Union
Biopharmaceuticals Cardiology Regulatory

HSMN NewsFeed - 24 Jul 2015
FDA approves Novartis drug Odomzo(R) (sonidegib) for locally advanced basal cell carcinoma (laBCC), a form of skin cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 24 Jul 2015
Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent(R) (alirocumab) for the Treatment of Hypercholesterolemia
Biopharmaceuticals Regulatory

HSMN NewsFeed - 6 Apr 2015
European Commission Approves Amgen's Vectibix(R) (panitumumab) As First-Line Treatment In Combination With FOLFIRI Chemotherapy For Metastatic Colorectal Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 7 Jan 2015
Mundipharma receives positive European Commission decision on Targin(R) (oxycodone/naloxone) for the treatment of Restless Legs Syndrome1
Biopharmaceuticals Regulatory

HSMN NewsFeed - 12 Dec 2014
Sanofi Pasteur Announces FDA Approval of Fluzone(R) Intradermal Quadrivalent (Influenza Vaccine) for Adults
Biopharmaceuticals FDA

HSMN NewsFeed - 25 Nov 2014
Valeant Pharmaceuticals Announces FDA Approval Of ONEXTON(TM) Gel For The Treatment Of Acne Vulgaris
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 27 Aug 2014
Ligand Partner GlaxoSmithKline Receives U.S. FDA Approval for Promacta(R)/Revolade(TM) For Use in Patients with Severe Aplastic Anemia
Biopharmaceuticals FDA

HSMN NewsFeed - 25 Jul 2014
Bayer and Onyx Pharmaceuticals Report Phase 3 Trial Results of NEXAVAR(R) (sorafenib) in Patients with Advanced Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2014
Trevi Therapeutics Announces $25 Million Series B Financing Led by TPG Biotech for Development of Nalbuphine ER
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 19 Mar 2014
Mallinckrodt plc Completes $1.4 Billion Acquisition of Cadence Pharmaceuticals, Inc.
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 11 Mar 2014
Lumena Pharmaceuticals Raises $45 Million in Series B Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 11 Mar 2014
Bayer and Onyx Report Phase 3 Study Results of NEXAVAR(R) (sorafenib) as Adjuvant Treatment for Patients with Liver Cancer Who Have Undergone Surgery or Local Ablation
Biopharmaceuticals Oncology

HSMN NewsFeed - 7 Mar 2014
Incyte Announces Positive Top-Line Results from Phase III Study of Ruxolitinib in Patients with Polycythemia Vera
Biopharmaceuticals

HSMN NewsFeed - 3 Mar 2014
U.S. FDA Approves Bydureon(R) Pen (exenatide extended-release for injectable suspension) for Once-Weekly Treatment of Adults with Type 2 Diabetes
Biopharmaceuticals Drug Delivery Endocrinology FDA

HSMN NewsFeed - 11 Feb 2014
Mallinckrodt plc to Acquire Cadence Pharmaceuticals, Inc. for $14.00 Per Share, in Cash
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 31 Jan 2014
Valeant Pharmaceuticals Announces Approval of Retin-A Micro(R) Microsphere 0.08%
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 3 Jan 2014
Iroko’s ZORVOLEX(TM) Now Available
Biopharmaceuticals Product Launch

HSMN NewsFeed - 13 Dec 2013
Genzyme’s Lemtrada(TM) Approved in Canada for Treatment of Multiple Sclerosis
Biopharmaceuticals Neurology Regulatory

HSMN NewsFeed - 18 Oct 2013
Cimzia(R) (Certolizumab Pegol) Approved by FDA for Treatment of Adults with Active Ankylosing Spondylitis
Biopharmaceuticals FDA

HSMN NewsFeed - 30 Sep 2013
Cimzia(R) (certolizumab pegol) approved by the U.S. FDA for treatment of adult patients with active psoriatic arthritis
Biopharmaceuticals FDA

HSMN NewsFeed - 17 Sep 2013
European Commission Approves Genzyme’s Multiple Sclerosis Treatment Lemtrada(TM) (alemtuzumab)
Biopharmaceuticals Neurology Regulatory

HSMN NewsFeed - 18 Jul 2013
Celgene Will Discontinue Phase III ORIGIN(R) Trial in Previously Untreated Elderly Patients with B-Cell Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 Feb 2013
CSL Behring Receives FDA Approval to Expand the Indication for Corifact(R)
Biopharmaceuticals Surgery FDA

HSMN NewsFeed - 28 Feb 2013
Pernix Therapeutics Receives FDA Approvals
Biopharmaceuticals FDA

HSMN NewsFeed - 21 Jan 2013
Mallinckrodt Announces Approval of New Gablofen(R) Prefilled Syringe
Biopharmaceuticals Drug Delivery Neurology FDA

HSMN NewsFeed - 25 Jun 2012
Baxter Announces FDA Approval for GAMMAGARD LIQUID as a Treatment for Multifocal Motor Neuropathy
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 27 Apr 2012
Baxter Presents Efficacy and Safety Data Evaluating GAMMAGARD LIQUID for Multifocal Motor Neuropathy at AAN Annual Meeting
Biopharmaceuticals Neurology

HSMN NewsFeed - 26 Jan 2012
LEO Pharma Announces That Picato(R) (ingenol mebutate) gel has Been Approved by US FDA for Once-Daily, 2 or 3 day Treatment of Actinic Keratoses
Biopharmaceuticals Dermatology

HSMN NewsFeed - 25 Jan 2012
FDA Approves Picato(R) (ingenol mebutate) Gel, the First and Only Topical Actinic Keratosis (AK) Therapy With 2 or 3 Consecutive Days of Once-Daily Dosing
Biopharmaceuticals Drug Delivery Dermatology FDA

HSMN NewsFeed - 1 Nov 2011
FDA Approves Addition of Sustained Overall Survival Advantage (5-year follow-up) to Label for VELCADE(R) in Patients with Previously Untreated Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 15 Sep 2011
Astellas and Theravance Announce European Marketing Authorization for VIBATIV(R) for Nosocomial Pneumonia Caused by MRSA
Biopharmaceuticals Regulatory

HSMN NewsFeed - 31 Aug 2011
Baxter Announces FDA Approval of ARTISS Fibrin Sealant for Use in Face-Lift (Facial Rhytidectomy) Procedures
Devices FDA

HSMN NewsFeed - 25 Jul 2011
Baxter Announces FDA Approval of Subcutaneous Route of Administration for GAMMAGARD LIQUID for Patients with Primary Immunodeficiency
Biopharmaceuticals FDA

HSMN NewsFeed - 1 Jul 2011
Merck Receives Approval to Market GARDASIL(R), ZOLINZA(R) and CUBICIN(R) in Japan
Biopharmaceuticals Regulatory

HSMN NewsFeed - 24 Mar 2011
FDA Expands Indication for ZOSTAVAX(R), Merck’s Shingles Vaccine, to Include Adults Ages 50 to 59
Biopharmaceuticals FDA

HSMN NewsFeed - 15 Mar 2011
Incyte’s Ruxolitinib (INCB18424) Meets Primary Endpoint in Second Phase III Study
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Feb 2011
FDA Approves Makena, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth
Biopharmaceuticals FDA

HSMN NewsFeed - 18 Jan 2011
Cadence Pharmaceuticals Announces U.S. Launch and Availability of OFIRMEV (acetaminophen) Injection
Biopharmaceuticals

HSMN NewsFeed - 22 Dec 2010
US FDA Approves New Indication for Merck's HPV Vaccine, GARDASIL(R)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 6 Dec 2010
XIAFLEX(R) Effective in Nonsurgically Treating MP and PIP Joints with Dupuytren's Contractures in Second Pivotal Study
Biopharmaceuticals

HSMN NewsFeed - 19 Nov 2010
NeurogesX Receives Qutenza(R)-Specific J-Code From Centers for Medicare and Medicaid Services (CMS)
Biopharmaceuticals Drug Delivery Reimbursement

HSMN NewsFeed - 11 Nov 2010
FDA Approves EGRIFTA(TM) (Tesamorelin for Injection): The First and Only Treatment for the Reduction of Excess Abdominal Fat in HIV-Infected Patients With Lipodystrophy
Biopharmaceuticals FDA

HSMN NewsFeed - 2 Nov 2010
Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV (acetaminophen) injection for the Management of Pain and Fever
Biopharmaceuticals FDA

HSMN NewsFeed - 31 Aug 2010
Allergan, Inc. Receives FDA Approval for LUMIGAN(R) 0.01% as First-Line Therapy Indicated for the Reduction of Elevated Intraocular Pressure in Glaucoma Patients
Biopharmaceuticals Ophthalmology FDA

HSMN NewsFeed - 20 Aug 2010
REVLIMID(R) Approved for Treatment of Deletion 5q Myelodysplastic Syndromes in Japan
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 10 Aug 2010
Phase 3 ILLUMINATE Study Supports 24-Week Telaprevir-Based Therapy Within a Response-Guided Regimen for People with Hepatitis C Who Had Not Received Prior Treatment
Biopharmaceuticals

HSMN NewsFeed - 15 Jul 2010
Provectus Pharmaceuticals Reports Achieved Milestones for First Half of 2010, Recent Developments and Plans for the Remainder of the Year to Shareholders
Biopharmaceuticals Dermatology Oncology

HSMN NewsFeed - 8 Jun 2010
Salix Pharmaceuticals Announces NDA Submission For XIFAXAN550 For Treatment of Non-Constipation Irritable Bowel Syndrome
Biopharmaceuticals Gastroenterology FDA

HSMN NewsFeed - 4 Jun 2010
New Data at ASCO Show Novartis Drug Tasigna(R) Surpasses Gleevec(R) for Newly Diagnosed CML Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 25 May 2010
Genzyme Receives FDA Approval for Lumizyme for Pompe Disease
Biopharmaceuticals FDA

HSMN NewsFeed - 10 May 2010
Takeda to Co-Promote VELCADE(R) (bortezomib) for Injection in Japan
Biopharmaceuticals Oncology

HSMN NewsFeed - 6 Apr 2010
Baxter and Nycomed Announce FDA Approval of TachoSil(R)
Devices Surgery FDA

HSMN NewsFeed - 1 Apr 2010
AMAG Pharmaceuticals and Takeda Pharmaceutical Company Announce Strategic Collaboration for Feraheme(R) in All Therapeutic Indications in Select Ex-US Territories, Including Europe
Biopharmaceuticals Licensing

HSMN NewsFeed - 24 Mar 2010
FDA Approves XIFAXAN(R) 550 MG Tablets for Reduction in Risk of Overt Hepatic Encephalopathy (HE) Recurrence
Biopharmaceuticals FDA

HSMN NewsFeed - 19 Feb 2010
Novartis Drug Tasigna(R) Receives FDA Priority Review for Newly Diagnosed Patients With Early-Stage Chronic Myeloid Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 17 Feb 2010
In Phase III Data Merck's GARDASIL(R) Was Efficacious Against Anal Disease Caused by HPV-6,11,16 and 18
Biopharmaceuticals

HSMN NewsFeed - 21 Jan 2010
Amgen Presents Complete Results From Two Pivotal Phase 3 Studies of Vectibix(R) at Gastrointestinal Cancers Symposium
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jan 2010
FDA Approves Addition of Sustained Overall Survival Benefit to Label for VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 23 Dec 2009
Lilly, Kowa and Kowa Pharmaceuticals America Announce Co-Promotion and Licensing Agreement
Biopharmaceuticals Cardiology Licensing

HSMN NewsFeed - 8 Dec 2009
Novartis Tasigna(R) Trial Shows Superior Results to Gleevec(R) in Patients With Early-Stage Chronic Myeloid Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 7 Dec 2009
VELCADE(R) (Bortezomib) for Injection Based Combinations Deliver Two-Year Overall Survival Rates of Up to 88 Percent in Patients with Previously Untreated Multiple Myeloma
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 Dec 2009
Dyax Announces FDA Approval of KALBITOR(R) (ecallantide) for the Treatment of Acute Attacks of Hereditary Angioedema in Patients 16 Years of Age and Older
Biopharmaceuticals FDA

HSMN NewsFeed - 27 Nov 2009
Theravance Receives Complete Response Letter on the Telavancin NDA for the Treatment of Nosocomial Pneumonia
Biopharmaceuticals FDA

HSMN NewsFeed - 13 Nov 2009
Phase II/III Clinical Study Compares Safety and Efficacy of Two Doses of ZENPEP(TM) (Pancrelipase) Delayed-Release Capsules for Fat Absorption in Adult Chronic Pancreatitis Patients With Exocrine Pancreatic Insufficiency
Biopharmaceuticals

HSMN NewsFeed - 5 Nov 2009
Theravance and Astellas Announce the Commercial Launch of VIBATIV(TM) (telavancin) in the United States
Biopharmaceuticals

HSMN NewsFeed - 5 Nov 2009
Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Oct 2009
New Data Describe Safety of Subcutaneous Administration of ORENCIA(R) (abatacept) For Patients with Moderate to Severe Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 20 Oct 2009
Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Oct 2009
Talecris Biotherapeutics Receives FDA Approval for PROLASTIN(R)-C
Biopharmaceuticals FDA

HSMN NewsFeed - 17 Oct 2009
FDA Approves GARDASIL(R) for Use in Boys and Young Men
Biopharmaceuticals FDA

HSMN NewsFeed - 1 Oct 2009
Astellas and Theravance Announce Approval of VIBATIV(TM) (telavancin) in Canada for the Treatment of Complicated Skin and Skin Structure Infections
Biopharmaceuticals Regulatory

HSMN NewsFeed - 24 Sep 2009
Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in First-Line Metastatic Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 23 Sep 2009
Data Presented from Two Phase 3 ERBITUX(R) Studies in First-Line Metastatic Colorectal Cancer Patients at Joint 15th European Cancer Organisation and 34th European Society for Medical Oncology Multidisciplinary Congress
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Sep 2009
Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in Second-Line Metastatic Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 Sep 2009
FDA Grants Priority Review Status to Supplement Containing Long-Term Survival Data for VELCADE(R) (bortezomib) for Injection
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 2 Sep 2009
FDA Advisory Committee Recommends Gloucester Pharmaceuticals' Romidepsin for Approval for Cutaneous T-cell Lymphoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 2 Sep 2009
FDA to Review Supplement Containing Long-Term Survival Data For VELCADE(R) (bortezomib) For Injection
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 30 Aug 2009
New Large-Scale, Global Study Provides Additional Information About an Intensified Dose-Regimen of Plavix(R) in Acute Coronary Syndrome Patients Undergoing Angioplasty
Biopharmaceuticals Interventional Cardiology

HSMN NewsFeed - 28 Aug 2009
Eurand Granted FDA Approval for ZENPEP(TM)
Biopharmaceuticals FDA

HSMN NewsFeed - 20 Jul 2009
ImClone Systems and Bristol-Myers Squibb Announce Revisions to ERBITUX(R) (cetuximab) U.S. Product Labeling for Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 30 Jun 2009
FDA Approves Feraheme to Treat Iron Deficiency Anemia in Adult Chronic Kidney Disease Patients
Biopharmaceuticals FDA

HSMN NewsFeed - 26 Jun 2009
Dermatologic and Ophthalmic Drugs Advisory Committee Unanimously Recommends Bepreve(TM) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 12 Jun 2009
Clinical Data Presented at International Congress Showed Treatment With Neupro(R) (rotigotine) Significantly Improved Early Morning akinesia and was Generally Well Tolerated Over Four Years
Biopharmaceuticals Neurology

HSMN NewsFeed - 29 May 2009
UCB receives CHMP positive opinion on bringing Neupro(R) back to all patients in Europe
Biopharmaceuticals Neurology Regulatory

HSMN NewsFeed - 29 May 2009
Bausch & Lomb Receives FDA Approval of Besivance(TM), New Topical Ophthalmic Antibacterial for the Treatment of Bacterial Conjunctivitis ('Pink Eye')
Biopharmaceuticals Ophthalmology FDA

HSMN NewsFeed - 18 May 2009
AstraZeneca Announces TOPROL-XL(R) (Metoprolol Succinate) is Now Available
Biopharmaceuticals

HSMN NewsFeed - 13 May 2009
AZOR(R) Receives FDA Approval as First-Line Treatment for High Blood Pressure
Biopharmaceuticals FDA

HSMN NewsFeed - 8 May 2009
New Data Shows AZOR(R) (Amlodipine and Olmesartan Medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure
Biopharmaceuticals Cardiology

HSMN NewsFeed - 7 May 2009
New Once-Daily RYZOLT(TM) (tramadol HCl extended-release tablets) Now Available in the U.S.
Biopharmaceuticals

HSMN NewsFeed - 7 Apr 2009
Aplenzin(TM), the Only Single Tablet Once-Daily Treatment for Depression at All Doses, Now Available in the United States
Biopharmaceuticals

HSMN NewsFeed - 19 Mar 2009
Genzyme Receives Positive Opinion for European Approval of Renvela for Patients with Kidney Disease
Biopharmaceuticals Regulatory

HSMN NewsFeed - 5 Mar 2009
European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors
Biopharmaceuticals Oncology FDA Regulatory

HSMN NewsFeed - 2 Mar 2009
ImClone Systems and Bristol-Myers Squibb Update Status of First-Line Squamous Cell Carcinoma of the Head and Neck Supplemental Biologics Application for ERBITUX(R) in U.S.
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 20 Feb 2009
UCB to divest Equasym(R)
Biopharmaceuticals Acquisitions

HSMN NewsFeed - 3 Feb 2009
Galderma Wins FDA Approval for Vectical(TM) Ointment, a Novel Topical Therapy for Mild-to-Moderate Plaque Psoriasis
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 27 Jan 2009
Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients
Biopharmaceuticals

HSMN NewsFeed - 23 Jan 2009
ImClone Systems and Bristol-Myers Squibb Update the Status of Non-Small Cell Lung Cancer Supplemental Biologics Application Submission for ERBITUX(R)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 15 Jan 2009
ISTA Pharmaceuticals' New Drug Application for Bepreve(TM) Accepted for Review by U.S. Food and Drug Administration
Biopharmaceuticals Ophthalmology FDA

HSMN NewsFeed - 9 Jan 2009
Merck & Co., Inc. Receives Complete Response Letter from the Food and Drug Administration for Use of GARDASIL(R) in Women Ages 27 through 45
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 8 Dec 2008
ERBITUX® Supplemental Biologics License Application for Advanced Non-Small Cell Lung Cancer Submitted to U.S. Food and Drug Administration
Biopharmaceuticals Oncology

HSMN NewsFeed - 6 Dec 2008
Rituxan in Combination with Chemotherapy Improves Progression-Free Survival in Difficult-to-Treat Form of Blood Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 13 Nov 2008
GARDASIL®, Merck's Cervical Cancer Vaccine, Demonstrated Efficacy in Preventing HPV-Related Disease in Males in Phase III Study
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Oct 2008
ImClone Announces ERBITUX(R) Commercial Launch in Canada for Advanced Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 Oct 2008
Perrigo Company Licenses Prescription Brands to Medimetriks Pharmaceuticals
Biopharmaceuticals Licensing

HSMN NewsFeed - 22 Oct 2008
Study Published in New England Journal of Medicine Shows K-ras Gene Mutation Status May Affect Response to ERBITUX(R) Treatment
Biopharmaceuticals Oncology

HSMN NewsFeed - 21 Oct 2008
Abbott's HUMIRA(R) (adalimumab) Data Shows Fistula Healing for Up to Three Years in Patients with Moderate to Severe Crohn's Disease
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 10 Oct 2008
FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
Biopharmaceuticals FDA

HSMN NewsFeed - 6 Oct 2008
Lilly to Acquire ImClone Systems in $6.5 Billion Transaction
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 19 Sep 2008
ERBITUX(R) Now Available in Japan for Use in Treating Patients with Advanced Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 Sep 2008
Continuous Treatment With Abbott's HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment
Biopharmaceuticals Dermatology

HSMN NewsFeed - 16 Sep 2008
ImClone Provides Update on Pivotal Phase 3 CRYSTAL Study in First-Line Metastatic Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Sep 2008
ImClone Submits Supplemental Biologics License Application for ERBITUX(R) in First-Line Head and Neck Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Aug 2008
ERBITUX(R) Phase 3 BMS-099 Lung Cancer Study Secondary Endpoint Update: Overall Survival Results Announced
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 Aug 2008
New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 Aug 2008
Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 16 Jul 2008
ERBITUX(R) (Cetuximab) Receives Approval in Japan for Use in Advanced Colorectal Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 14 Jul 2008
ImClone Announces Changes in Commercial Organization Leadership
Biopharmaceuticals Personnel

HSMN NewsFeed - 11 Jul 2008
TREDAPTIVE(TM) (nicotinic acid /laropiprant) Approved in the European Union: New Lipid-Modifying Therapy to Treat LDL-C, HDL-C and Triglycerides
Biopharmaceuticals Cardiology Regulatory

HSMN NewsFeed - 13 Jun 2008
Data Show that Abbott's HUMIRA(R) (adalimumab) Reduced the Signs and Symptoms of Ankylosing Spondylitis Up to Three Years
Biopharmaceuticals

HSMN NewsFeed - 13 Jun 2008
HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity
Biopharmaceuticals

HSMN NewsFeed - 13 Jun 2008
New Long-Term HUMIRA(R) (adalimumab) Data Show Up to Seven-Year Efficacy with Combination Treatment for Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 2 Jun 2008
ImClone Appoints Dr. Bernhard Ehmer Senior Vice President and Managing Director, International Operations
Biopharmaceuticals Personnel

HSMN NewsFeed - 1 Jun 2008
New Analyses of Pivotal Phase 3 Study of ERBITUX(R) Demonstrate Enhanced Efficacy in First-Line Metastatic Colorectal Cancer Patients with Wild-Type K-Ras Biomarker
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 Jun 2008
Updated Data from Ongoing Phase 3 Trials Support the Continued Study of Vectibix(R) (panitumumab) in Combination with Standard Chemotherapy
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 May 2008
ERBITUX(R) (Cetuximab) Data Demonstrate Improved Overall Survival in First-Line Treatment of Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 21 May 2008
Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
Biopharmaceuticals

HSMN NewsFeed - 16 May 2008
ERBITUX(R) (cetuximab) Data Demonstrate Improvements in Response Rate and Progression-Free Survival in Wild Type K-Ras Metastatic Colorectal Cancer Patients in First-Line Setting
Biopharmaceuticals Oncology

HSMN NewsFeed - 15 May 2008
CDC Recommends ZOSTAVAX(R), Merck's Shingles Vaccine, for All Appropriate Adults Aged 60 and Older
Biopharmaceuticals

HSMN NewsFeed - 29 Apr 2008
Genentech and Biogen Idec Announce Top-Line Results from Phase II/III Clinical Study of Rituxan in Systemic Lupus Erythematosus
Biopharmaceuticals

HSMN NewsFeed - 25 Apr 2008
European Commission Approves Viread(R) for Chronic Hepatitis B
Biopharmaceuticals Regulatory

HSMN NewsFeed - 16 Apr 2008
Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 20 Mar 2008
Baxter Announces FDA Approval of ARTISS Slow-Setting Fibrin Sealant in Treatment of Burn Patients
Devices FDA

HSMN NewsFeed - 6 Mar 2008
Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
Biopharmaceuticals

HSMN NewsFeed - 3 Mar 2008
Endo Pharmaceuticals to Launch Three New Dosage Strengths of OPANA(R) ER
Biopharmaceuticals Pain Management FDA

HSMN NewsFeed - 29 Feb 2008
U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
Biopharmaceuticals FDA

HSMN NewsFeed - 27 Feb 2008
Manhattan Pharmaceuticals Announces Closing of Joint Venture With Nordic Biotech
Biopharmaceuticals

HSMN NewsFeed - 24 Jan 2008
KRAS Gene Status May Impact Vectibix(TM) (Panitumumab) Efficacy and Patient Reported Outcomes in Advanced Colorectal Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 23 Jan 2008
FDA Approves Additional Indication for Astellas' MYCAMINE(R)
Biopharmaceuticals FDA

HSMN NewsFeed - 14 Jan 2008
Roche responds to announcement of 'IDEAL' hepatitis C trial results
Biopharmaceuticals

HSMN NewsFeed - 7 Jan 2008
Alkermes Announces Agreement for the Commercialization of VIVITROL in Russia/CIS
Biopharmaceuticals

HSMN NewsFeed - 20 Dec 2007
Abbott's HUMIRA(R) Approved in the European Union for Treatment of Moderate-to-Severe Plaque Psoriasis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 5 Dec 2007
Vectibix(R) Approved in the European Union for the Treatment of Metastatic Colorectal Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 29 Nov 2007
Published Data Suggest That ERBITUX(R) Enables Complete Surgical Resection of Colorectal Liver Metastases in Patients Previously Refractory to Conventional Systemic Therapy
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 Nov 2007
Tasigna(R) gains European approval for patients with a life-threatening form of leukemia who are resistant or intolerant to existing therapies
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 16 Nov 2007
Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 14 Nov 2007
New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Nov 2007
New Data Presented on GARDASIL(R), Merck's Cervical Cancer Vaccine, in Women Through Age 45
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Nov 2007
Treatment with PEGASYS(R)/COPEGUS(TM) Provides Hope for Hepatitis C Patients Whose Infection Did Not Initially Respond to Peg-Intron(R)/Ribavirin
Biopharmaceuticals

HSMN NewsFeed - 2 Nov 2007
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Biopharmacetuicals

HSMN NewsFeed - 2 Nov 2007
First Studies Demonstrating Greater than Sixty Percent Sustained Viral Response Rates with Half the Standard Treatment Duration in Genotype 1 Chronic Hepatitis C Patients
Biopharmaceuticals

HSMN NewsFeed - 1 Nov 2007
Dawn McGuire, M.D. Joins Acologix, Inc. as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 31 Oct 2007
Allergan, Inc. Receives FDA Approval for COMBIGAN(TM) (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5%
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 30 Oct 2007
Significant New Data on Roche's PEGASYS(R) and Hepatitis C Pipeline Compounds to be Featured at 58th Annual AASLD Meeting
Biopharmaceuticals

HSMN NewsFeed - 29 Oct 2007
Tasigna(R) receives US approval providing new hope to chronic myeloid leukemia patients with resistance or intolerance to existing therapies
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 29 Oct 2007
Gilead Announces 48-Week Data Evaluating Switching from Combivir(R) To Truvada(R) Among Virologically-Suppressed HIV Patients
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 17 Oct 2007
ImClone and Bristol-Myers Squibb Announce Joint Agreement with Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Oct 2007
Interim Results from a New Trial of CANCIDAS(R) (caspofungin acetate) in Pediatric Patients with Documented Fungal Infections
Biopharmaceuticals

HSMN NewsFeed - 2 Oct 2007
Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 27 Sep 2007
FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 27 Sep 2007
MGI PHARMA Announces Submission of Aquavan(R) New Drug Application
Biopharmaceuticals FDA

HSMN NewsFeed - 26 Sep 2007
ISTA Pharmaceuticals Expands Its Pipeline in Allergy Treatments
Biopharmaceuticals Licensing

HSMN NewsFeed - 25 Sep 2007
New Biomarker Data Links KRAS Gene to Vectibix(TM) Clinical Response
Biopharmaceuticals Oncology

HSMN NewsFeed - 21 Sep 2007
Vectibix(TM) (panitumumab) Receives Positive Opinion for Marketing Authorization in the European Union
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 18 Sep 2007
New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
Biopharmaceuticals

HSMN NewsFeed - 17 Sep 2007
Study Presented on Use of CANCIDAS(R) (caspofungin acetate) as Empirical Therapy of Suspected Invasive Fungal Infections in Pediatric Patients with Persistent Fever and Neutropenia
Biopharmaceuticals

HSMN NewsFeed - 4 Sep 2007
Oral Cancer Drug REVLIMID(R) Receives Swissmedic Approval in Switzerland for Treatment of Multiple Myeloma
Biopharmaceuticals Regulatory Oncology

HSMN NewsFeed - 25 Jul 2007
A.T.S. Pharmaceuticals, A division of Auriga Laboratories Launches Xyralid(TM) LP Lotion
Biopharmaceuticals Dermatology

HSMN NewsFeed - 23 Jul 2007
144-Week Data from Gilead's Study 934 Comparing Truvada(R) to Combivir(R) Both in Combination with Sustiva(R) Presented At International AIDS Society Meeting in Sydney
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 19 Jun 2007
REVLIMID(R) Granted Full Marketing Authorization for Treatment of Multiple Myeloma in the European Union
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 15 Jun 2007
Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia(R) (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
Biopharmaceuticals

HSMN NewsFeed - 15 Jun 2007
Bradley Pharmaceuticals Launches Peranex(TM) HC Cream
Biopharmaceuticals

HSMN NewsFeed - 15 Jun 2007
Three Studies Suggest Abbott's HUMIRA(R) (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 14 Jun 2007
Barrier Therapeutics Announces Liarozole Phase 2/3 Study Results in Lamellar Ichthyosis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 7 Jun 2007
Abbott's HUMIRA(R) (Adalimumab) Approved in the European Union for the Treatment of Crohn's Disease
Biopharmaceuticals Gastroenterology Regulatory

HSMN NewsFeed - 4 Jun 2007
ONTAK(R) (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2007
The Eloxatin(R)-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Jun 2007
FOLFOX4 (Eloxatin(R)-based Chemotherapy) After Surgery Improves Overall Survival in Patients With Early (Stage III) Colon Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 25 May 2007
Amgen to Appeal CHMP Opinion on Vectibix(TM) (Panitumumab)
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 15 May 2007
SWOG Phase III Newly Diagnosed Multiple Myeloma Trial (S0232) Closed and Patients Given Choice to Switch to REVLIMID(R) Plus Dexamethasone
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 May 2007
ISTA Pharmaceuticals Announces Statistically Significant Preliminary Results From its U.S. Phase II/III Clinical Study Of Bepotastine
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 30 Apr 2007
Humate-P(R) Approved to Prevent Excessive Bleeding in Patients with von Willebrand Disease Undergoing Surgery
Biopharmaceuticals FDA

HSMN NewsFeed - 30 Apr 2007
Cyclacel Pharmaceuticals Begins Phase II Study of Oral Sapacitabine in Patients with Advanced Cutaneous T-Cell Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 Apr 2007
Abbott's HUMIRA(R) (Adalimumab) Receives Positive Opinion from European Medicines Agency for the Treatment of Crohn's Disease
Biopharmaceuticals Gastroenterology Regulatory

HSMN NewsFeed - 24 Apr 2007
Ceragenix Announces Results from Phase IV Study of EpiCeram(TM) Meet All Primary and Secondary Endpoints
Biopharmaceuticals Dermatology

HSMN NewsFeed - 4 Apr 2007
ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports LENALIDOMIDE Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma
Biopharmaceuticals Oncology

HSMN NewsFeed - 23 Mar 2007
Oral Cancer Drug REVLIMID(R) Receives Positive Opinion for Treatment of Multiple Myeloma From European Medicines Agency
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 22 Mar 2007
Amgen Discontinues Vectibix(TM) Treatment in Pacce Trial Evaluating Vectibix(Tm) as Part of Triple Combination Regimen
Biopharmaceuticals Oncology

HSMN NewsFeed - 15 Jan 2007
Genzyme Announces Publication of Study Showing Impact of Cerezyme on Bone Health for Patients With Type 1 Gaucher Disease
Biopharmaceuticals

HSMN NewsFeed - 12 Jan 2007
Astellas Pharma US, Inc. Announces Availability of MYCAMINE(R) 100mg Vial
Biopharmaceuticals

HSMN NewsFeed - 26 Dec 2006
Astellas Pharma US, Inc. Submits Supplemental New Drug Application For Antifungal Product MYCAMINE(R)
Biopharmaceuticals FDA

HSMN NewsFeed - 19 Dec 2006
Endo Pharmaceuticals Submits Citizen Petition to FDA Regarding Lidoderm(R)
Biopharmaceuticals Drug Delivery Generics FDA

HSMN NewsFeed - 12 Dec 2006
Gloucester Pharmaceuticals Reports Clinically Significant Responses in Interim Analysis of Pivotal Trial for Cutaneous T-Cell Lymphoma at the 2006 American Society of Hematology (ASH) Annual Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Dec 2006
49 Abstracts Evaluating Revlimid(R) To Be Presented at The 48th American Society of Hematology Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 21 Nov 2006
Par Pharmaceutical Begins Shipment of Generic TOPROL-XL(R)
Biopharmaceuticals Generics Distribution

HSMN NewsFeed - 14 Nov 2006
Nabi Biopharmaceuticals Closes Sale of PhosLo(R) to Fresenius Medical Care
Biopharmaceuticals

HSMN NewsFeed - 13 Nov 2006
Interim Analysis of New Study Suggests Boosted INVIRASE(R) May Achieve Similar Levels of HIV Suppression to Boosted Lopinavir with a Favorable Lipid Profile
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 7 Nov 2006
SkinMedica and Galderma to Co-Promote Desonate(TM)
Biopharmaceuticals Dermatology

HSMN NewsFeed - 2 Nov 2006
Ranbaxy Receives Tentative Approval to Manufacture and Market Cetirizine Hydrochloride Syrup
Biopharmaceuticals Generics FDA

HSMN NewsFeed - 30 Oct 2006
New Study Shows Sculptra(R) (injectable poly-L-lactic acid), a Unique Class of Injectable for Cosmetic Use, Provides 13 Month Results
Biopharmaceuticals Dermatology

HSMN NewsFeed - 23 Oct 2006
SkinMedica(R) Announces FDA Approval of Desonate(TM) (Desonide) Gel 0.05% With Patented Hydrogel Technology for Treatment of Atopic Dermatitis
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 17 Oct 2006
Endo Pharmaceuticals Comments on Lidoderm(R)
Biopharmaceuticals Generics

HSMN NewsFeed - 16 Oct 2006
Nabi Biopharmaceuticals Announces Positive Results From PhosLo(R) EPICK Study
Biopharmaceuticals

HSMN NewsFeed - 12 Oct 2006
Nabi Biopharmaceuticals Signs Definitive Agreement To Sell PhosLo(R) To Fresenius Medical Care
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 5 Oct 2006
New Phase III Data Show Abbott's HUMIRA(R) (Adalimumab) Was Statistically Superior to Methotrexate in Patients With Psoriasis
Biopharmaceuticals

HSMN NewsFeed - 2 Oct 2006
Updated REVLIMID(R) (lenalidomide) Clinical Results Presented at the 3rd International Conference on Innovative Therapies for Lymphoid Malignancies
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 Sep 2006
FDA Approves Vectibix(TM) to Treat Patients with Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 24 Jul 2006
Endo Announces Commercial Availability of Opana(R) ER (oxymorphone HCl) Extended-Release and Opana(R) (oxymorphone HCl) Immediate-Release Tablets CII
Biopharmaceuticals

HSMN NewsFeed - 18 Jul 2006
Nabi Biopharmaceuticals Releases New Data which Demonstrate Superior Serum Phosphorus Control with PhosLo(R) (calcium acetate) over Sevelamer
Biopharmaceuticals

HSMN NewsFeed - 29 Jun 2006
REVLIMID(R) in Combination With Dexamethasone sNDA Granted Approval By FDA for Treatment of Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 23 Jun 2006
Allergan Announces FDA Approval of LUMIGAN(R) as First-Line Treatment for Elevated Eye Pressure in Open-Angle Glaucoma
Biopharmaceuticals Ophthalmology FDA

HSMN NewsFeed - 23 Jun 2006
Endo Receives FDA Approval for Opana(R) ER (oxymorphone HCl) Extended-Release and Opana(R) (oxymorphone HCl) Immediate Release Tablets CII
Biopharmaceuticals FDA

HSMN NewsFeed - 26 May 2006
FDA Approves ZOSTAVAX(R), Merck's New Vaccine for Prevention of Shingles in Adults Age 60 and Older
Biopharmaceuticals FDA

HSMN NewsFeed - 24 May 2006
UCB Completes Mutual Recognition Procedure for Equasym(TM) XL
Biopharmaceuticals Regulatory

HSMN NewsFeed - 8 May 2006
Medicis Announces FDA Approval of SOLODYN -- minocycline HCl, USP -- Extended Release Tablets
Biopharmaceuticals Dermatology FDA

Return to NewsFeed

Additional items found! 124

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 124 additional stories matching:
pruritus
(Password required)

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!